Skip to main content
\
IXI™ Platform

IXI™ Platform

AI-Driven Neuroimaging Biomarker Science for Clinical Trials

IXI™ is IXICO’s proprietary, AI-enabled neuroimaging technology platform for precision medicine, purpose-built to drive clinical trial imaging and biomarker science insights in neurological disease research.

The platform integrates standardised high-quality image data capture, image reading, advanced analysis, and regulatory-compliant reporting of clinical data, enabling the biopharma industry to develop new medicines and diagnostic measures via a single end-to-end platform. 

/assets/FullWidthImages/IXI-Platform-Dark-S.png

Insights derived from imaging biomarker data

Regions Blank W

IXI™ facilitates AI-powered biomarker discovery, validation, and analysis, enabling deeper insights into disease progression, treatment response, and patient stratification.

Key Capabilities:

  • Advanced Imaging Modalities
    Supports a wide range of MRI and PET/SPECT biomarkers, including:
    • MRI: Structural T1/T2, DTI, fMRI, MRS, ASL, QSM, neuromelanin
    • PET/SPECT: Amyloid, Tau, FDG, TSPO, DAT, α-synuclein
  • AI-Driven Biomarker Quantification
    Delivers automated volumetric analysis and disease staging, which have been validated across a number of neurodegenerative therapeutic areas.
  • Novel AI Algorithms and Operational Pipelines
    Incorporates cutting-edge, proprietary AI neuroimaging models for academic research  innovation  and clinical trial use—bridging the gap between early-stage research and clinical application. These validated, scalable biomarker pipelines are deployed on behalf of biopharma clients, enabling confident and efficient integration into global trials.
  • Combine Analytics and Insights from Other Biomarkers
    Leverage imaging, digital, and fluid biomarkers together for rich, multidimensional data and deeper clinical insight.
  • Consultative Science
    Expert-led imaging endpoint definition, protocol optimisation, and statistical modelling to maximise trial sensitivity and reduce cohort sizes.
  • Post-Marketing Surveillance & Decision Support
    Extends biomarker insights into real-world evidence generation and clinical decision-making.
Gradient

Platform Highlights

AI-Enabled Imaging Analysis

Automates complex image processing tasks, improving speed, accuracy, and reproducibility.

Global Scalability

Proven infrastructure supporting multi-site, multi-country trials with centralised oversight.

Regulatory compliance and security

IXI™ ensures the compliance required by regulatory agencies together with best practice industry standards such as ICH-GCP, 21 CFR Part 11, ISO-13485 and ISO/EC-27001

Modular & Customizable

Adaptable to sponsor needs, therapeutic areas, and trial phases.

Seamless Integration

Compatible with sponsor systems and workflows, requiring no additional software.

Key Features

End-to-End Workflow  From trial design and imaging site setup to data upload, quality control, and regulatory-compliant transfer, the IXI™ Platform ensures seamless clinical trial execution.
IXI™ Platform Interface A secure, cloud-based portal for real-time image tracking, upload, pseudonymization, and query resolution across thousands of imaging sites worldwide.
Automated Quality Control & Scan Validation Automated tools within the IXI Platform assess scan quality, protocol compliance, and standardisation, ensuring imaging data is trial-ready and regulatory-grade.
Centralised Radiology Reads Flexible read workflows and bespoke read forms support blinded, multi-reader, and adjudicated reads—tailored to each protocol and therapeutic area.
Global Imaging Site Network Over 2,000 qualified imaging sites across 75+ countries, trained and supported by IXICO’s expert teams.
Regulatory Compliance Fully aligned with GCP, ISO13485, ISO/IEC27001, and CFR Part 11 standards.
Patient-Centric Trial Management Tailored protocols and support for neurological patient populations, ensuring ease of participation and high-quality data capture.

Gradient

Platform Evolution

The IXI™ Platform continues to evolve, expanding its capabilities beyond clinical trials into diagnostics, real-world evidence, and AI-enhanced clinical decision support. With a foundation in neuroscience and a commitment to innovation, IXICO is shaping the future of neuroimaging through:

Next-Generation Biomarkers

Including fluid biomarkers and hybrid imaging modalities.

AI-Driven Disease Modelling

Supporting earlier diagnosis, patient stratification, and predictive analytics through analysis automation.

Precision Medicine Applications

Enabling targeted therapies and individualized treatment monitoring.

Built for flexibility, scale and expansion

A flexible architecture that integrates bespoke workflows to deliver imaging endpoints with AI automated analysis tools and third-party pipelines.